-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 LT9nrEOnFKJx1r9PbjjnwrZ16R8YLeqU5Q2HmwqAOEj5YDDenFihjH7iOgvBhFF3
 KnElkKYAuZNhpvQtR5LdRw==

<SEC-DOCUMENT>0000950123-09-042158.txt : 20090910
<SEC-HEADER>0000950123-09-042158.hdr.sgml : 20090910
<ACCEPTANCE-DATETIME>20090909175003
ACCESSION NUMBER:		0000950123-09-042158
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20090901
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20090910
DATE AS OF CHANGE:		20090909

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MILESTONE SCIENTIFIC INC/NJ
		CENTRAL INDEX KEY:			0000855683
		STANDARD INDUSTRIAL CLASSIFICATION:	ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
		IRS NUMBER:				133545623
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14053
		FILM NUMBER:		091061301

	BUSINESS ADDRESS:	
		STREET 1:		220 S ORANGE AVE
		STREET 2:		LIVINGSTON CORPORATE PARK
		CITY:			LIVINGSTON
		STATE:			NJ
		ZIP:			07039
		BUSINESS PHONE:		2013793171

	MAIL ADDRESS:	
		STREET 1:		44 KEAN ROAD
		STREET 2:		220 SOUTH ORANGE AVE
		CITY:			LIVINGSTON
		STATE:			NJ
		ZIP:			07039

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	U S OPPORTUNITY SEARCH INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>c90083e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">



<DIV style="font-size: 10pt">
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>


<P align="center" style="font-size: 14pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION<BR>
<FONT style="font-size: 12pt">Washington, D.C. 20549
</FONT></B>

<P align="center" style="font-size: 18pt"><B>FORM 8-K</B>

<P align="center" style="font-size: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</B>

<P align="center" style="font-size: 10pt"><B>Date of Report (Date of earliest event reported): September 1, 2009</B>

<P align="center">

<P align="center" style="font-size: 24pt"><B>MILESTONE SCIENTIFIC INC.<BR></B>
<FONT style="font-size: 10pt">(Exact name of registrant as specified in its charter)
</FONT>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="32%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="33%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="32%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>Delaware</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>001-14053</B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>13-3545623</B></TD>
</TR>
<TR valign="top">
    <TD>(State or other Jurisdiction of Incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD>(Commission File Number)</TD>
    <TD>&nbsp;</TD>
    <TD>(IRS Employer Identification No.)</TD>
</TR>
</TABLE>

<TABLE border="0" width="100%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="49%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD style="border-bottom: 1px solid #000000"><B>220 South Orange Avenue, Livingston Corporate Park, Livingston, New Jersey <BR></B></TD>
    <TD>&nbsp;</TD>
    <TD style="border-bottom: 1px solid #000000"><B>07034</B></TD>
</TR>
<TR valign="top">
    <TD>(Address of Principal Executive Offices)</TD>
    <TD>&nbsp;</TD>
    <TD>(Zip Code)</TD>
</TR>
</TABLE>

<P align="center" style="font-size: 10pt">Registrant&#146;s telephone number, including area code: <B>(973) 535-2717</B>


<TABLE border="0" width="30%" cellspacing="0" cellpadding="0" style="font-size: 10pt; text-align: center">
<TR>
    <TD width="100%">&nbsp;</TD>
</TR>
<TR>
    <TD nowrap style="border-bottom: 1px solid #000000"><B>N/A<BR></B></TD>
</TR>
<TR>
    <TD nowrap>(Former name or former address if changed since last report.)</TD>
</TR>
</TABLE>

<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:

<P align="left" style="font-size: 10pt">
<FONT face="Wingdings">&#111;</FONT> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))<BR><BR>
<FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))<BR>


<P>
<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>

</DIV>

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">1
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt">
    <TD width="3%" nowrap align="left"><B>Item 5.02:&nbsp;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.</B></TD>
</TR>

</TABLE>




<P align="left" style="font-size: 10pt; text-indent: 4%">On September&nbsp;1, 2009, Leonard Osser was appointed as Milestone&#146;s Chief Executive Officer. Mr.&nbsp;Osser had been
Milestone&#146;s Interim Chief Executive Officer since March&nbsp;2009. Mr.&nbsp;Osser previously served as Milestone&#146;s Chief
Executive Officer from 1991 to 2007.


<P align="left" style="font-size: 10pt; text-indent: 5%">Pursuant to his appointment as Chief Executive Officer, Mr.&nbsp;Osser entered into an Employment Agreement (the
&#147;Agreement&#148;) with Milestone, effective September&nbsp;1, 2009. The term of the Agreement is for a five year period ending
on August&nbsp;31, 2014. Under the Agreement, Mr.&nbsp;Osser will receive a base compensation of $300,000 per year. In addition,
Mr.&nbsp;Osser may earn annual bonuses up to an aggregate of $400,000, payable one half in cash and one half in common
stock, contingent upon Milestone achieving predetermined goals and targets as defined in the Agreement.


<P align="left" style="font-size: 10pt; text-indent: 5%">In addition, if in any year of the term of the Agreement Mr.&nbsp;Osser earns a bonus, he shall also be granted
five-year stock options to purchase twice the number of shares earned. Each such option is to be exercisable at a price
per share equal to the fair market value of a share on the date of grant (110% of the fair market value if Mr.&nbsp;Osser is
a 10% or greater stockholder on the date of grant). The options shall vest and become exercisable to the extent of
one-third of the shares covered at the end of each of the first three years following the date of grant, but shall only
be exercisable while Mr.&nbsp;Osser is employed by Milestone or within 30&nbsp;days after the termination of the Agreement.

<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt">
    <TD width="3%" nowrap align="left"><B>Item&nbsp;8.01:&nbsp;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Other Matters.</B></TD>
</TR>

</TABLE>



<P align="left" style="font-size: 10pt; text-indent: 4%">On September&nbsp;1, 2009, we issued a press release, a copy of which is attached hereto as Exhibit&nbsp;99.1.

<P>
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt">
    <TD width="3%" nowrap align="left"><B>Item&nbsp;9.01:&nbsp;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Financial Statements and Exhibits</B></TD>
</TR>

</TABLE>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="10%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="7%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="67%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top" align="right"><DIV style="margin-left:0px; text-indent:-0px">(d)
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap colspan="4" align="center" valign="top">Exhibits:
</TD>
     <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD colspan="7">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" valign="top">&nbsp;</TD>
    <TD align="right" valign="top">99.1</TD>
    <TD nowrap valign="top">&nbsp;</TD>
     <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press Release dated September&nbsp;1, 2009.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>



<P align="left" style="font-size: 10pt; text-indent: 4%">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly authorized.



<P align="left" style="margin-left:48%; font-size: 10pt"><B>MILESTONE SCIENTIFIC INC.</B>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="49%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
<TD>&nbsp;</TD>
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">By:
</DIV></TD>

    <TD align="left" valign="top">/s/ Leonard Osser</TD>
</TR>
<TR style="font-size: 1px">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Leonard Osser<BR>
Chief Executive Officer</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="left" style="font-size: 10pt">Dated: September&nbsp;1, 2009

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">2
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>c90083exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Exhibit 99.1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P align="right" style="font-size: 10pt">Exhibit&nbsp;99.1



<P align="center" style="font-size: 10pt"><B>MILESTONE SCIENTIFIC ANNOUNCES KEY LEADERSHIP CHANGES</B>



<P align="center" style="font-size: 10pt"><B><I>Director Leslie Bernhard Appointed as New Chairman and Leonard Osser<BR>
Resumes Full Duties and Responsibilities as CEO</I></B>



<P align="left" style="font-size: 10pt"><B><I>PISCATAWAY, N.J. &#150; (PR NEWSWIRE) &#150; September&nbsp;1, 2009 </I></B>&#150; Milestone Scientific Inc. (OTCBB:MLSS), the recognized leader in
advanced injection technologies, today announced that Leslie Bernhard, an independent director, has been named Chairman
of the Board, succeeding Leonard Osser who had previously led the Company as Chairman since 1991. Osser, who has also
served as the interim Chief Executive Officer since February&nbsp;2009 and was formerly Milestone&#146;s CEO from 1991 through
2007, will again lead the Company as its CEO effective immediately.


<P align="left" style="font-size: 10pt">&#147;In view of Leonard&#146;s passion, vision and well defined strategy for optimizing Milestone&#146;s future growth, having him
resume the full duties and responsibilities of the CEO post is without question in the best interests of the Company,
its dedicated workforce and its shareholders,&#148; stated new Chairman Bernhard. &#147;Moreover, by my assuming the
Chairmanship, the Board can take advantage of enhancing our corporate governance and oversight, while freeing Leonard
to concentrate on achieving the Company&#146;s mission critical goals and objectives.&#148;


<P align="left" style="font-size: 10pt">Commenting on the leadership changes, Osser noted, &#147;We are now seeing a number of promising growth opportunities in the
international markets related to the expansion of our global dental distribution network and worldwide marketing of our
award winning <I>STA Single Tooth Anesthesia System</I><SUP style="font-size: 85%; vertical-align: text-top"><I>&#153;</I></sup><I>. </I>We are also gaining meaningful traction in our
negotiations in collaborating on the development of new medical products utilizing our patented <I>CompuFlo</I><SUP style="font-size: 85%; vertical-align: text-top">&#174;</sup>
technology. Consequently, the Board determined that my time and effort was best utilized focused on fully capitalizing
on these promising opportunities. As such, I&#146;m very pleased that Leslie has agreed to assume leadership of the Board.
In my capacity as a director and CEO, I look forward to working closely with her to help guide and manage our Company&#146;s
long term growth and anticipated success.&#148;


<P align="left" style="font-size: 10pt"><B>About Milestone Scientific Inc.</B>
<BR>
Headquartered in Piscataway, New Jersey, Milestone Scientific is engaged in pioneering proprietary, highly innovative
technological solutions for the medical and dental markets.&nbsp; Central to the Company&#146;s IP platform and product
development strategy is its patented <I>CompuFlo</I><SUP style="font-size: 85%; vertical-align: text-top">&#174;</sup> technology for the improved and painless delivery of local
anesthetic. Specifically, <I>CompuFlo </I>is a computer-controlled, pressure sensitive infusion, perfusion, suffusion and
aspiration technology, which provides real-time readouts of pressures, fluid densities and flow rates, enabling the
advanced delivery and removal of a wide array of fluids.&nbsp; The <I>STA Single Tooth Anesthesia System</I><SUP style="font-size: 85%; vertical-align: text-top"><I>&#153;</I></sup><I>, </I>a
computer-controlled local anesthesia delivery system, uses this technology to provide dentists with audible and visual
signals as to in-tissue pressure. Milestone&#146;s existing painless injection systems are currently sold in 25 countries.
For more information on these and other innovative Milestone products, please visit the Company&#146;s web site found at
<U>www.milestonescientific.com</U> and <U>www.STAis4U.com</U>.

<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">3
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif; margin-left: .25in; width: 7.20in">

<P align="left" style="font-size: 10pt"><B><I>Safe Harbor Statement</I></B>
<BR>
<I>This press release contains forward-looking statements regarding the timing and financial impact of the Milestone&#146;s
ability to implement its business plan, expected revenues and future success. These statements involve a number of
risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive
and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and
many of which are beyond Milestone&#146;s control. Some of the important factors that could cause actual results to differ
materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve
expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments,
competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from
time to time in Milestone&#146;s periodic filings with the Securities and Exchange Commission, including without limitation,
Milestone&#146;s Annual Report for the year ended December&nbsp;31, 2008. The forward looking-statements in this press release
are based upon management&#146;s reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or
update publicly any forward-looking statements for any reason.</I>


<P align="center" style="font-size: 10pt"><B>FOR MORE INFORMATION, PLEASE CONTACT:<BR>
Elite Financial Communications Group<BR>
Dodi Handy, President and CEO (</B><B><I>Twitter: @dodihandy</I></B><B>)<BR>
For Media Inquiries: Kathy Addison, Director, Elite Media Group (Twitter: @</B><B><I>kathyaddison</I></B><B>)<BR>
407-585-1080 or via email at </B><U><B><I>mlss@efcg.net</I></B></U>



<P align="center" style="font-size: 10pt">&nbsp;

<P align="center" style="font-size: 10pt; display: none">4




</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
